Latest Biotech News

Parabilis Medicines set a record for biotech going public by pricing a $670 million IPO at $20 per share, topping prior 2026 listings in the sector. The oncology-focused company—formerly Fog...

SonoThera raised $125 million in a Series B to advance its ultrasound-based gene therapy platform into the clinic. The company’s approach uses microbubbles activated by ultrasound to enhance...

GSK agreed to acquire Nuvalent for about $10.6 billion in cash, securing two late-stage lung cancer medicines under FDA review: zidesamtinib (ROS1) and neladalkib (ALK). The acquisition reinforces...

Incyte agreed to acquire Vega Therapeutics for up to $2 billion, aiming to expand its hematology pipeline with VGA039, a Phase III von Willebrand disease candidate. The deal adds a monoclonal...

Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, acquiring a degrader antibody conjugate (DAC) platform along with development capabilities. The transaction adds to the market...

Merck and Gilead reported mixed results across two Phase 3 areas: Gilead’s Trodelvy missed in first-line lung cancer, while a once-weekly oral HIV combination program showed success. The Trodelvy...

JP Morgan upgraded Illumina to Overweight from Neutral and set a $185 price target, citing growing visibility into demand for sequencers and consumables. The analyst highlighted customer...

African and European regulators are preparing trials for Bundibugyo Ebola vaccines and therapeutic options in the Democratic Republic of the Congo and Uganda. Reporting indicates multiple products...

Geneoscopy said CMS added its ColoSense stool-based RNA test to the National Coverage Determination for colorectal cancer screening. The update creates a coverage framework that supports future...

Sanofi has stopped a Phase 3 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board concluded the therapy was unlikely to achieve...

Parabilis Medicines—formerly FogPharma—has priced an upsized $670 million biotech IPO, setting a new record for venture-backed drug companies going public. The offering totals 33.3 million shares...

Novartis has signed a second molecular-glue partnership with Orionis Biosciences, adding $40 million upfront and up to $1.4 billion in milestone-based consideration. The deal focuses on Orionis’s...

SonoThera has raised $125 million to advance its ultrasound-based, non-viral gene therapy platform into the clinic. The funding round is led by Vida Ventures, with participation from large pharma...

GSK has agreed to buy Nuvalent for roughly $10.6 billion in cash, a move designed to add two late-stage lung cancer programs to its pipeline. The deal brings ROS1 inhibitor zidesamtinib and ALK...

JP Morgan upgraded Illumina to Overweight from Neutral, arguing the sequencing platform’s customer retention and spend outlook have become clearer. The bank cited survey work with 62 Illumina...

Geneoscopy’s stool-based RNA colorectal screening test, ColoSense, has received coverage under a National Coverage Determination from the U.S. Centers for Medicare and Medicaid Services. The...

A pair of separate launches highlight rising interest in modality-first gene delivery and platform integration. In one case, SonoThera’s funding accelerates its pathway into clinical evaluation...

Incyte has agreed to acquire Vega Therapeutics for up to $2 billion, aiming to strengthen its hematology pipeline with VGA039, a Phase III von Willebrand disease (VWD) candidate. Vega is a Star...

Japan has granted marketing approval to Oncolys Biopharma’s oncolytic adenovirus Telomelysin (suratadenoturev, OBP-301) for treating esophageal cancer patients who are not eligible for curative...

Geneoscopy said the U.S. Centers for Medicare and Medicaid Services expanded national coverage for colorectal cancer screening tests to include its ColoSense stool-based RNA assay. The update adds...